BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Akebia Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Akebia Therapeutics's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07268638-940@assetmemo.bio
DTSTAMP:20261121T005029Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Praliciguat: Phase 2 readout est. (NCT07268638)
DESCRIPTION:Praliciguat\, phase 2\, Chronic Kidney Disease.\nStudy: A Study
  of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (F
 SGS)\nEstimated primary completion: June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/praliciguat#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07268638
URL:https://assetmemo.bio/drug/praliciguat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06419205-5759@assetmemo.bio
DTSTAMP:20261121T005029Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Ebribafusp alfa: Phase 2 readout est. (NCT06419205)
DESCRIPTION:Ebribafusp alfa\, phase 2\, IgA Nephropathy.\nStudy: A Phase 2 
 Study to Evaluate the Safety\, PD\, PK\, and Clinical Activity of ADX-097 
 in Participants With IgAN\, LN or C3G\nEstimated primary completion: Febru
 ary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ebribafusp-
 alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06419205
URL:https://assetmemo.bio/drug/ebribafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
